Stroke Clinical Trial
Official title:
Effects of Using the Electrodress Mollii to Reduce Spasticity and Enhance Functioning After Stroke.
Verified date | August 2019 |
Source | Danderyd Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Spasticity is a common manifestation of lesions of central motor pathways, such as after stroke, traumatic brain or spinal cord injury and in cerebral palsy and is associated with increased impairments and disabilities. Spasticity may be associated with pain and contractures, caused by muscle weakness, reduced muscle length and volume that add to the disability.Treatments of spasticity comprise physical therapy, pharmacological agents and surgical treatment. Recently, a systematic review concluded that transcutaneous, electric nerve stimulation may have beneficial effects on spasticity and activity performance after stroke, which lends support to the new treatment method Mollii, which will be evaluated in this study.The Mollii suit provides electric stimulation through multiple electrodes places in a tight fitting suit. This study relates to the clinical trials performed at the University department of rehabilitation medicine at Danderyd Hospital in Stockholm and comprises an initial study of effects on spasticity ("Mechanical substudy") and a following, exploratory treatment trial ("Clinical substudy") in patients with spasticity after stroke.
Status | Completed |
Enrollment | 21 |
Est. completion date | February 1, 2019 |
Est. primary completion date | February 1, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Eligible participants had - suffered a stroke > 12 months earlier - were living with hemiplegia affecting the right or the left side of the body including both upper and lower extremity function - were able to walk with assistance or independently according to the Functional Ambulatory Categories (Holden 1984) with a score of 2-5 - activity in upper extremity was limited according to the Action Research Arm test (ARAT) (Nordin 2014) but could perform a grasp and grip movement - were > 17 years old, able to understand instructions as well as written and oral study information and could express informed consent Exclusion Criteria: - no detected neural component exceeding the cut off for spasticity according to the Neuroflexor (> 3. 4 Newton) in the wrist flexors - contractures not compatible with performing the Neurofexor test or walking - any other disorder with an impact on sensorimotor function - any other severe concomitant disease (such as cancer, cardiovascular, inflammatory or psychiatric disease), uncontrolled epilepsy or blood pressure, major surgery during the last year, any implanted medical devices - pregnancy - BMI>35 |
Country | Name | City | State |
---|---|---|---|
Sweden | Department of Rehabilitation Medicine, Danderyd Hospital | Danderyd | Stockholm |
Lead Sponsor | Collaborator |
---|---|
Danderyd Hospital |
Sweden,
Gäverth J, Eliasson AC, Kullander K, Borg J, Lindberg PG, Forssberg H. Sensitivity of the NeuroFlexor method to measure change in spasticity after treatment with botulinum toxin A in wrist and finger muscles. J Rehabil Med. 2014 Jul;46(7):629-34. doi: 10.2340/16501977-1824. — View Citation
Gäverth J, Sandgren M, Lindberg PG, Forssberg H, Eliasson AC. Test-retest and inter-rater reliability of a method to measure wrist and finger spasticity. J Rehabil Med. 2013 Jul;45(7):630-6. doi: 10.2340/16501977-1160. — View Citation
Lindberg PG, Gäverth J, Islam M, Fagergren A, Borg J, Forssberg H. Validation of a new biomechanical model to measure muscle tone in spastic muscles. Neurorehabil Neural Repair. 2011 Sep;25(7):617-25. doi: 10.1177/1545968311403494. Epub 2011 Apr 13. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mechanism substudy and Clinical substudy: NeuroFlexor | Measure related to spasticity: The Neuroflexor device comprises a portable computer-controlled step motor system with a lever arm that generates constant velocity movements of the wrist or ankle. The passive resistive force of the wrist or ankle is recorded by a force transducer. The force is then analyzed off-line and the total resistance is separated into mechanical and a neural components using a neuro-biomechanical computerized model. NeuroFlexor neural component reflecting stretch reflex mediated resistance, represents the main outcome. The NeuroFlexor hand (used in mechanism and clinical substudy) and foot module (used in mechansim substudy only) is a valid method that quantifies and distinguishes the genuine spasticity and the mechanical contributions (viscoelastic and soft tissue components) of the resistance opposing a passive stretch. | Mechanism study: To assess change, NeuroFlexor data is recorded before, during and 10 minutes after treatment at each session. Clinical study: To assess change Neuroflexor data is collected before and after the 6 week intervention. | |
Secondary | Mechanism substudy: Surface electromyography | Measure related to spasticity: Surface electromyography (sEMG) signal of spastic muscles in the upper and lower limb (flexor carpi radialis, medial gastrocnemius and soleus muscles). | To assess change sEMG are assessed before and after 60 min of treatment at each session. | |
Secondary | Mechanism substudy: Modified Ashworth scale: | Clinical assessment of spasticity on a 5 point scale ranging from 0= no spasticity to 5= rigidity | Before and after 60 min of treatment at each session to assess change | |
Secondary | Mechanism substudy: Semi structured interview | To assess perceived effects of each intervention | During the 60 min of treatment at each session | |
Secondary | Clinical substudy: the Fugl-Meyer scale | Clinical assessment of motor sensory function of the upper (min 0 p and max 126p) and lower extremity (min 0 p and max 86p). Max point indicates no detected impairment. | Before and after the 6 week intervention to assess change | |
Secondary | Clinical substudy: Modified Ashworth scale | Clinical assessment of spasticity on a 5 point scale ranging from 0= no spasticity to 5= rigidity | Before and after the 6 week intervention to assess change | |
Secondary | Clinical substudy: Barthel Index | Assessment of self-care and mobility (min 0 p and max 100p). Max point indicates independence | Before and after the 6 week intervention to assess change | |
Secondary | Clinical substudy: Berg balance scale | Clinical assessment of balance (max 56p). Max point indicate no limitations in balance. | Before and after the 6 week intervention to assess change | |
Secondary | Clinical substudy: Montreal Cognitive Assessment | Assessment of cognitive function (min 0 p and max 30p). Max point indicate no impairment. | Before and after the 6 week intervention to assess change | |
Secondary | Clinical substudy: Action Research Arm Test | Clinical assessment of activity in upper extremity (max 57 p). Max point indicate no limitation. | Before and after the 6 week intervention to assess change | |
Secondary | Clinical substudy: A digital hand dynamometer | Clinical assessment of grip strength in kilograms. | Before and after the 6 week intervention to assess change | |
Secondary | Clinical substudy: 10 meter walk test | Clinical assessment of walking speed (m/s) | Before and after the 6 week intervention to assess change | |
Secondary | Clinical substudy: 6 min walk test | Clinical assessment of walking endurance (meters) | Before and after the 6 week intervention to assess change | |
Secondary | Clinical substudy: Functional Ambulation Category | Assessment of indedence in walking (min 0 p and max 5p) Max point indicate independence | Before and after the 6 week intervention to assess change | |
Secondary | Clinical substudy: Stroke Impact Scale | Self-perceived functioning and disability (min 0 p and max 100p/item). Max point indicate no perceived disability. | Before and after the 6 week intervention to assess change | |
Secondary | Clinical substudy: Weekly semistructured telephone interview | To assess compliance, perceived effects and adverse events. | Weekly during the 6 week intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Recruiting |
NCT03869138 -
Alternative Therapies for Improving Physical Function in Individuals With Stroke
|
N/A | |
Completed |
NCT04101695 -
Hemodynamic Response of Anodal Transcranial Direct Current Stimulation Over the Cerebellar Hemisphere in Healthy Subjects
|
N/A | |
Completed |
NCT04034069 -
Effects of Priming Intermittent Theta Burst Stimulation on Upper Limb Motor Recovery After Stroke: A Randomized Controlled Trial
|
N/A | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Completed |
NCT00391378 -
Cerebral Lesions and Outcome After Cardiac Surgery (CLOCS)
|
N/A | |
Recruiting |
NCT06204744 -
Home-based Arm and Hand Exercise Program for Stroke: A Multisite Trial
|
N/A | |
Active, not recruiting |
NCT06043167 -
Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
|
||
Active, not recruiting |
NCT04535479 -
Dry Needling for Spasticity in Stroke
|
N/A | |
Completed |
NCT03985761 -
Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke
|
N/A | |
Recruiting |
NCT00859885 -
International PFO Consortium
|
N/A | |
Recruiting |
NCT06034119 -
Effects of Voluntary Adjustments During Walking in Participants Post-stroke
|
N/A | |
Completed |
NCT03622411 -
Tablet-based Aphasia Therapy in the Chronic Phase
|
N/A | |
Completed |
NCT01662960 -
Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke
|
N/A | |
Recruiting |
NCT05854485 -
Robot-Aided Assessment and Rehabilitation of Upper Extremity Function After Stroke
|
N/A | |
Active, not recruiting |
NCT05520528 -
Impact of Group Participation on Adults With Aphasia
|
N/A | |
Completed |
NCT03366129 -
Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
|
||
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Completed |
NCT05805748 -
Serious Game Therapy in Neglect Patients
|
N/A | |
Recruiting |
NCT05621980 -
Finger Movement Training After Stroke
|
N/A |